ARCHIVES

FDA Sets High Bar for Prevention Agents as ODAC Votes Down Proscar And Avodart

This article is from The Cancer Letter archive.

Vol. 36 No. 44 | December 3, 2010

Download PDF Visit The Full Archive

Related Articles

In Brief: NCAB Lacked Courage On Some Special Actions, Amos Says; Pick Reviewers On Ability Only, Scientist Asks

July 30, 1982

Research Program For Biological Response Modifiers Outlined By DCT board Subcommittee

November 16, 1979

Centers Program Needs ‘Innovative Additions’ Such as SPORE Grants

September 20, 1991

Mayo Clinic Study Finds Samarium May Expand Options For Osteosarcoma

February 22, 2002

Reauthorization Battle Warms Up; Administration, But Not Wyngaarden, May OK Cancer Act Renewal

March 18, 1988

Chemo Combinations Tested In Phase III For Lung Cancer

August 31, 2001